Research Article
Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study
Table 2
Observed and expected numbers and standardized incidence ratios for cancers among the male and female workers employed in asbestos-related factories.
| Cancer type | Males | Females | Obs. N.O. | Exp. N.O. | SIR (95% CI) | Obs. N.O. | Exp. N.O. | SIR (95% CI) |
| All cancers | 6544 | 13731.1 |
(0.47–0.49) | 1894 | 2357.8 | (0.77–0.84) | Lip, oral cavity, and pharynx | 726 | 1206.1 | 0.60 (0.56–0.65) | 20 | 27.62 | 0.72 (0.44–1.12) | Major salivary glands | 26 | 29.58 | 0.88 (0.57–1.29) | 6 | 5.79 | 1.04 (0.38–2.25) | Nasopharynx | 363 | 439.58 | (0.74–0.92) | 43 | 39.62 | 1.09 (0.79–1.46) | Esophagus | 241 | 378.2 | (0.56–0.72) | 5 | 5.62 | 0.89 (0.29–2.08) | Stomach | 409 | 591.48 | (0.63–0.76) | 58 | 76.96 | (0.57–0.97) | Colon, rectum, and anus | 872 | 5186.73 | (0.16–0.18) | 147 | 623.28 | (0.20–0.28) | Liver and intrahepatic bile ducts | 1280 | 1971.02 | (0.61–0.69) | 120 | 143.87 | (0.69–1.00) | Gall bladder and extrahepatic bile ducts | 45 | 87.53 | (0.37–0.69) | 9 | 16.64 | 0.54 (0.25–1.03) | Pancreas | 104 | 167.71 | (0.51–0.75) | 19 | 23.64 | 0.80 (0.48–1.25) | Nose, middle ear, and sinuses | 18 | 34.84 | (0.31–0.82) | 1 | 4.14 | 0.24 (0.01–1.35) | Larynx | 86 | 139.96 | (0.49–0.76) | 3 | 1.77 | 1.69 (0.35–4.95) | Trachea, bronchus, and lung | 758 | 1222.97 | (0.58–0.67) | 123 | 144.80 | 0.85 (0.71–1.01) | Retroperitoneum | 6 | 13.99 | (0.16–0.93) | 4 | 3.95 | 1.01 (0.28–2.60) | Pleura (malignant mesothelioma) | 17 | 6.41 | (1.54–4.25) | 1 | 0.60 | 1.67 (0.04–9.29) | Bone and articular cartilage | 15 | 19.54 | 0.77 (0.43–1.27) | 2 | 4.41 | 0.45 (0.05–1.64) | Skin | 205 | 249.04 | 0.82 (0.71–0.94) | 43 | 44.04 | 0.98 (0.71–1.32) | Female breast | — | — | — | 494 | 493.63 | 1.00 (0.91–1.09) | Uterus and corpus uteri | — | — | — | 78 | 73.51 | 1.06 (0.84–1.32) | Cervix | — | — | — | 412 | 238.08 | 1.73 (1.57–1.91) | Adnexa (including ovary) | — | — | — | 53 | 67.28 | 0.79 (0.59–1.03) | Prostate | 307 | 459.99 | 0.67 (0.59–0.75) | — | — | — | Bladder | 234 | 310.72 | 0.75 (0.66–0.86) | 19 | 26.25 | 0.72 (0.44–1.13) | Kidney | 96 | 118.19 | 0.81* (0.66–0.99) | 11 | 26.77 | 0.41 (0.20–0.74) | Renal pelvis and ureter | 80 | 114.29 | 0.70 (0.56–0.87) | 21 | 14.77 | 1.42 (0.88–2.17) | Brain | 60 | 86.82 | 0.69 (0.53–0.89) | 15 | 16.10 | 0.93 (0.52–1.54) | Thyroid gland | 76 | 91.61 | 0.83 (0.65–1.04) | 91 | 88.98 | 1.02 (0.82–1.26) | Hodgkin lymphoma | 146 | 233.45 | 0.63 (0.53–0.74) | 3 | 2.27 | 1.32 (0.27–3.87) | Non-Hodgkin lymphoma | 6 | 12.96 | 0.46 (0.17–1.01) | 27 | 41.66 | 0.65* (0.43–0.94) | Leukemia | 118 | 165.06 | 0.71 (0.59–0.86) | 22 | 30.13 | 0.73 (0.46–1.11) | Others | 250 | 393.35 | 0.64 (0.56–0.72) | 44 | 71.68 | 0.61 (0.45–0.82) |
|
|
, . Obs. N.O.: observed number. Exp. N.O.: expected number; 95% CI: 95% confidence interval.
|